These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8680651)

  • 21. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia.
    Herrera L; Bostrom B; Gore L; Sandler E; Lew G; Schlegel PG; Aquino V; Ghetie V; Vitetta ES; Schindler J
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):936-41. PubMed ID: 19875969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor.
    Uckun FM; Messinger Y; Chen CL; O'Neill K; Myers DE; Goldman F; Hurvitz C; Casper JT; Levine A
    Clin Cancer Res; 1999 Dec; 5(12):3906-13. PubMed ID: 10632319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP; Coleman M; Ketas JC; Chadburn A; Furman R; Schuster MW; Feldman EJ; Ashe M; Schuster SJ; Wegener WA; Hansen HJ; Ziccardi H; Eschenberg M; Gayko U; Fields SZ; Cesano A; Goldenberg DM
    Clin Cancer Res; 2004 Aug; 10(16):5327-34. PubMed ID: 15328168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
    Grossbard ML; Gribben JG; Freedman AS; Lambert JM; Kinsella J; Rabinowe SN; Eliseo L; Taylor JA; Blättler WA; Epstein CL
    Blood; 1993 May; 81(9):2263-71. PubMed ID: 8481509
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
    Blakey DC; Watson GJ; Knowles PP; Thorpe PE
    Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS; Rodvien R; Grant K; Durrant LG; Hudson KH; Baldwin RW; Scannon PJ
    Cancer Res; 1989 Nov; 49(21):6153-60. PubMed ID: 2790828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML; Lambert JM; Goldmacher VS; Spector NL; Kinsella J; Eliseo L; Coral F; Taylor JA; Blättler WA; Epstein CL
    J Clin Oncol; 1993 Apr; 11(4):726-37. PubMed ID: 7683045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia.
    Schindler J; Gajavelli S; Ravandi F; Shen Y; Parekh S; Braunchweig I; Barta S; Ghetie V; Vitetta E; Verma A
    Br J Haematol; 2011 Aug; 154(4):471-6. PubMed ID: 21732928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
    Schindler J; Sausville E; Messmann R; Uhr JW; Vitetta ES
    Clin Cancer Res; 2001 Feb; 7(2):255-8. PubMed ID: 11234876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
    Durrant LG; Byers VS; Scannon PJ; Rodvien R; Grant K; Robins RA; Marksman RA; Baldwin RW
    Clin Exp Immunol; 1989 Feb; 75(2):258-64. PubMed ID: 2784738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins.
    Herrera L; Yarbrough S; Ghetie V; Aquino DB; Vitetta ES
    Leukemia; 2003 Feb; 17(2):334-8. PubMed ID: 12592332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
    Grossbard ML; Lambert JM; Goldmacher VS; Blättler WA; Nadler LM
    Cancer Res; 1992 Aug; 52(15):4200-7. PubMed ID: 1379121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New perspectives in oncology: is selective destruction of tumor cells with immunotoxins in Hodgkin's disease an additional therapeutic alternative?].
    Engert A; Gottstein C; Winkler U; Schön G; Amlot P; Thorpe P; Diehl V
    Med Klin (Munich); 1992 Oct; 87(10):503-9. PubMed ID: 1461215
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia.
    Hertler AA; Schlossman DM; Borowitz MJ; Laurent G; Jansen FK; Schmidt C; Frankel AE
    J Biol Response Mod; 1988 Feb; 7(1):97-113. PubMed ID: 3373237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
    Spitler LE; del Rio M; Khentigan A; Wedel NI; Brophy NA; Miller LL; Harkonen WS; Rosendorf LL; Lee HM; Mischak RP
    Cancer Res; 1987 Mar; 47(6):1717-23. PubMed ID: 3493066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
    Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
    Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.